Methotrexate Use in Scleroderma

Evidence for Methotrexate in Systemic Sclerosis

The European League Against Rheumatism recommends methotrexate for the treatment of skin manifestations in early diffuse systemic sclerosis, showing modest but beneficial effects on skin thickening 1, 2
Methotrexate may be considered for treatment of skin manifestations in early diffuse systemic sclerosis based on randomized controlled trials showing improvement in skin scores 3, 2
Two RCTs have evaluated methotrexate in systemic sclerosis, with one study showing a trend toward improvement in total skin score and another study showing a decrease in University of California Los Angeles skin score and modified Rodnan skin score compared to placebo 2, 4

Most clinical trials used relatively low doses of methotrexate (10-15 mg/week) 1, 2
Higher doses (up to 25 mg/week) are often prescribed in clinical practice but have not been formally studied in SSc 5

Safety concerns with methotrexate include liver toxicity, pancytopenia, potential teratogenicity, and possible induction of lung injury/interstitial lung disease 2
In clinical trials, there were few premature discontinuations due to adverse events 2

Methotrexate has stronger evidence for efficacy in juvenile localized scleroderma than in systemic sclerosis 6, 7
For active localized scleroderma, methotrexate is recommended in combination with systemic corticosteroids during the initial inflammatory phase 6, 7

Cyclophosphamide has also been shown in RCTs to improve skin changes in SSc patients and is the preferred agent for SSc-related interstitial lung disease 3, 1
Methotrexate showed a between-group difference of approximately 5 points in modified Rodnan skin score compared to placebo, though this did not reach statistical significance 5

Early diffuse cutaneous systemic sclerosis with predominant skin involvement is an indication for methotrexate 1, 2
Regular assessment of skin thickness using validated measures and monitoring for common side effects are necessary 1, 5, 6, 7
Liver function tests and complete blood counts should be performed regularly to detect hepatotoxicity and pancytopenia 2